Daniel L. Spitz

Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

Maurie Markman, James B. Hall, Daniel L. Spitz et al. · Journal of Clinical Oncology · 2002 · 210 citations

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

Jonathan Oh, Minal Barve, Carolyn M. Matthews et al. · Gynecologic Oncology · 2016 · 88 citations

Vigil® Dna, Medicine, Immunology +9

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Ignace Vergote, Agustin A. García, John P. Micha et al. · Journal of Clinical Oncology · 2013 · 52 citations · Full text

Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Ignace Vergote, John P. Micha, Charles H. Pippitt et al. · Journal of Clinical Oncology · 2010 · 26 citations

Platinum-resistant/refractory Ovarian Cancer, Refractory Ovarian Cancer, Phase Ii +14

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study

Sarina A. Piha‐Paul, Matthew H. Taylor, Daniel L. Spitz et al. · Oncotarget · 2019 · 26 citations · Full text